{
  "company": {
    "name": "CAMP4 Therapeutics",
    "website": "https://camp4tx.com/",
    "record": "https://startuphistory.org/c/camp4tx.com"
  },
  "status": null,
  "history_since": "2018-06-02T04:43:43.000Z",
  "baseline": {
    "snapshot_id": "6bde296036c52ae7c9998803425ac557ace4d7c2f5512752207fa41b1f9e2e0e",
    "observed_at": "2018-06-02T04:43:43.000Z",
    "headline": "CAMP4 is Solving the Gene Circuitry Code",
    "description": null,
    "evidence": "https://web.archive.org/web/20180602044343/https://www.camp4tx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T12:18:31.063Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2019-02-16T02:27:32.000Z",
      "variants": [
        {
          "headline": "CAMP4 is Solving the Gene Circuitry Code",
          "subhead": null,
          "observed_at": "2018-06-02T04:43:43.000Z",
          "evidence": "https://web.archive.org/web/20180602044343/https://www.camp4tx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "CAMP4 is Solving the Gene Circuitry Code",
          "subhead": null,
          "observed_at": "2019-02-16T02:27:32.000Z",
          "evidence": "https://web.archive.org/web/20190216022732/https://www.camp4tx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "CAMP4 is Solving the Gene Circuitry Code",
      "subhead": null,
      "from": "2018-06-02T04:43:43.000Z",
      "to": "2019-02-16T02:27:32.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20190216022732/https://www.camp4tx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2018-06-02T04:43:43.000Z",
          "to": "2019-02-16T02:27:32.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2025-08-06T06:40:11.000Z",
      "variants": [
        {
          "headline": "Client Challenge",
          "subhead": null,
          "observed_at": "2025-08-06T06:40:11.000Z",
          "evidence": "https://web.archive.org/web/20250806064011/https://www.camp4tx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Client Challenge",
      "subhead": null,
      "from": "2025-08-06T06:40:11.000Z",
      "to": "2025-08-06T06:40:11.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20250806064011/https://www.camp4tx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2025-08-06T06:40:11.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T12:18:31.063Z",
      "variants": [
        {
          "headline": "Pioneering a new class of RNA medicines to increase targeted gene expression",
          "subhead": "We are advancing a pipeline of first-in-class ASO-based therapeutics with the potential to address diseases caused by insufficient protein expression.",
          "observed_at": "2026-07-12T06:11:51.000Z",
          "evidence": "https://web.archive.org/web/20260712061151/https://www.camp4tx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Pioneering a new class of RNA medicines to increase targeted gene expression",
          "subhead": "We are advancing a pipeline of first-in-class ASO-based therapeutics with the potential to address diseases caused by insufficient protein expression.",
          "observed_at": "2026-10-15T07:51:52.000Z",
          "evidence": "https://web.archive.org/web/20261015075152/https://www.camp4tx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Pioneering a new class of RNA medicines to increase targeted gene expression",
          "subhead": "We are advancing a pipeline of first-in-class ASO-based therapeutics with the potential to address diseases caused by insufficient protein expression.",
          "observed_at": "2026-11-05T12:18:31.063Z",
          "evidence": "https://www.camp4tx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Pioneering a new class of RNA medicines to increase targeted gene expression",
      "subhead": "We are advancing a pipeline of first-in-class ASO-based therapeutics with the potential to address diseases caused by insufficient protein expression.",
      "from": "2026-07-12T06:11:51.000Z",
      "to": "2026-11-05T12:18:31.063Z",
      "captures": 3,
      "evidence": "https://www.camp4tx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-07-12T06:11:51.000Z",
          "to": "2026-11-05T12:18:31.063Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “CAMP4 Therapeutics” company record, https://startuphistory.org/c/camp4tx.com"
}